Literature DB >> 15003169

Androgen receptor YAC transgenic mice recapitulate SBMA motor neuronopathy and implicate VEGF164 in the motor neuron degeneration.

Bryce L Sopher1, Patrick S Thomas, Michelle A LaFevre-Bernt, Ida E Holm, Scott A Wilke, Carol B Ware, Lee-Way Jin, Randell T Libby, Lisa M Ellerby, Albert R La Spada.   

Abstract

X-linked spinal and bulbar muscular atrophy (SBMA) is an inherited neuromuscular disorder characterized by lower motor neuron degeneration. SBMA is caused by polyglutamine repeat expansions in the androgen receptor (AR). To determine the basis of AR polyglutamine neurotoxicity, we introduced human AR yeast artificial chromosomes carrying either 20 or 100 CAGs into mouse embryonic stem cells. The AR100 transgenic mice developed a late-onset, gradually progressive neuromuscular phenotype accompanied by motor neuron degeneration, indicating striking recapitulation of the human disease. We then tested the hypothesis that polyglutamine-expanded AR interferes with CREB binding protein (CBP)-mediated transcription of vascular endothelial growth factor (VEGF) and observed altered CBP-AR binding and VEGF reduction in AR100 mice. We found that mutant AR-induced death of motor neuron-like cells could be rescued by VEGF. Our results suggest that SBMA motor neuronopathy involves altered expression of VEGF, consistent with a role for VEGF as a neurotrophic/survival factor in motor neuron disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15003169     DOI: 10.1016/s0896-6273(04)00082-0

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  79 in total

Review 1.  Modifiers and mechanisms of multi-system polyglutamine neurodegenerative disorders: lessons from fly models.

Authors:  Moushami Mallik; Subhash C Lakhotia
Journal:  J Genet       Date:  2010-12       Impact factor: 1.166

2.  Inefficient degradation of truncated polyglutamine proteins by the proteasome.

Authors:  Carina I Holmberg; Kristine E Staniszewski; Kwame N Mensah; Andreas Matouschek; Richard I Morimoto
Journal:  EMBO J       Date:  2004-10-07       Impact factor: 11.598

3.  Native functions of the androgen receptor are essential to pathogenesis in a Drosophila model of spinobulbar muscular atrophy.

Authors:  Natalia B Nedelsky; Maria Pennuto; Rebecca B Smith; Isabella Palazzolo; Jennifer Moore; Zhiping Nie; Geoffrey Neale; J Paul Taylor
Journal:  Neuron       Date:  2010-09-23       Impact factor: 17.173

Review 4.  Therapeutic approaches to spinal and bulbar muscular atrophy.

Authors:  Srikanth Ranganathan; Kenneth H Fischbeck
Journal:  Trends Pharmacol Sci       Date:  2010-09-20       Impact factor: 14.819

5.  Contractile dysfunction in muscle may underlie androgen-dependent motor dysfunction in spinal bulbar muscular atrophy.

Authors:  Kentaro Oki; Katherine Halievski; Laura Vicente; Youfen Xu; Donald Zeolla; Jessica Poort; Masahisa Katsuno; Hiroaki Adachi; Gen Sobue; Robert W Wiseman; S Marc Breedlove; Cynthia L Jordan
Journal:  J Appl Physiol (1985)       Date:  2015-02-05

Review 6.  Modulation of Molecular Chaperones in Huntington's Disease and Other Polyglutamine Disorders.

Authors:  Sara D Reis; Brígida R Pinho; Jorge M A Oliveira
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

Review 7.  Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy.

Authors:  Jason P Chua; Andrew P Lieberman
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-12       Impact factor: 4.388

8.  Overexpression of wild-type androgen receptor in muscle recapitulates polyglutamine disease.

Authors:  Douglas Ashley Monks; Jamie A Johansen; Kaiguo Mo; Pengcheng Rao; Bryn Eagleson; Zhigang Yu; Andrew P Lieberman; S Marc Breedlove; Cynthia L Jordan
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-02       Impact factor: 11.205

9.  Effect of anti-VEGF antibody on retinal ganglion cells in rats.

Authors:  Aya Iriyama; Yi-Ning Chen; Yasuhiro Tamaki; Yasuo Yanagi
Journal:  Br J Ophthalmol       Date:  2007-05-02       Impact factor: 4.638

10.  The androgen receptor's CAG/glutamine tract in mouse models of neurological disease and cancer.

Authors:  Andrew P Lieberman; Diane M Robins
Journal:  J Alzheimers Dis       Date:  2008-06       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.